Caladrius Biosciences Inc is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. The company's current product candidates include three developmental treatments for cardiovascular diseases based on CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe, eligible for early conditional approval for the treatment of critical limb ischemia in Japan based on an ongoing clinical trial; CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial in the U.S.A. and CLBS14, a Phase 3 clinical program in no option refractory disabling angina and recipient of a RMAT designation in the U.S.A.